440 related articles for article (PubMed ID: 23622131)
1. Roles for KRAS in pancreatic tumor development and progression.
di Magliano MP; Logsdon CD
Gastroenterology; 2013 Jun; 144(6):1220-9. PubMed ID: 23622131
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas.
Park SW; Davison JM; Rhee J; Hruban RH; Maitra A; Leach SD
Gastroenterology; 2008 Jun; 134(7):2080-90. PubMed ID: 18549880
[TBL] [Abstract][Full Text] [Related]
3. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
4. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
5. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
6. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
[TBL] [Abstract][Full Text] [Related]
7. Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey.
Park JT; Johnson N; Liu S; Levesque M; Wang YJ; Ho H; Huso D; Maitra A; Parsons MJ; Prescott JD; Leach SD
Oncogene; 2015 May; 34(21):2801-6. PubMed ID: 25065594
[TBL] [Abstract][Full Text] [Related]
8. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
9. KRAS in pancreatic cancer.
Agarwal A; Saif MW
JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326
[TBL] [Abstract][Full Text] [Related]
10. Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia.
Ray KC; Moss ME; Franklin JL; Weaver CJ; Higginbotham J; Song Y; Revetta FL; Blaine SA; Bridges LR; Guess KE; Coffey RJ; Crawford HC; Washington MK; Means AL
Oncogene; 2014 Feb; 33(7):823-31. PubMed ID: 23376846
[TBL] [Abstract][Full Text] [Related]
11. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Zhang W; Li H; Yang Y; Liao J; Yang GY
Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
[TBL] [Abstract][Full Text] [Related]
12. Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo.
Ma Y; Gu Y; Zhang Q; Han Y; Yu S; Lu Z; Chen J
Mol Cancer Ther; 2013 Mar; 12(3):286-94. PubMed ID: 23288781
[TBL] [Abstract][Full Text] [Related]
13. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
14. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
Ferro R; Falasca M
World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
[TBL] [Abstract][Full Text] [Related]
16. Screening pancreatic oncogenes in zebrafish using the Gal4/UAS system.
Liu S; Leach SD
Methods Cell Biol; 2011; 105():367-81. PubMed ID: 21951538
[TBL] [Abstract][Full Text] [Related]
17. KRAS: feeding pancreatic cancer proliferation.
Bryant KL; Mancias JD; Kimmelman AC; Der CJ
Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.
Barceló C; Paco N; Morell M; Alvarez-Moya B; Bota-Rabassedas N; Jaumot M; Vilardell F; Capella G; Agell N
Cancer Res; 2014 Feb; 74(4):1190-9. PubMed ID: 24371225
[TBL] [Abstract][Full Text] [Related]
19. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
20. Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations.
Sawai Y; Kodama Y; Shimizu T; Ota Y; Maruno T; Eso Y; Kurita A; Shiokawa M; Tsuji Y; Uza N; Matsumoto Y; Masui T; Uemoto S; Marusawa H; Chiba T
Cancer Res; 2015 Aug; 75(16):3292-301. PubMed ID: 26113087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]